Corona Remedies' Q3 FY 2025-26 Quarterly Results

Result Summary

• Corona Remedies Ltd reported a 5.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a - of -.
• Its expenses for the quarter were down by 8.0% QoQ and - - YoY.
• The net profit decreased 21.1% QoQ and - - YoY.
• The earnings per share (EPS) of Corona Remedies Ltd stood at 6.75 during Q3 FY 2025-26.

Financial Statments for Q3 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

## Company Overview
Corona Remedies Ltd is a pharmaceutical company primarily involved in the manufacturing and distribution of pharmaceutical products. The company operates within the healthcare and pharmaceutical industry, which is characterized by its emphasis on research, development, and production of medications and healthcare products. As of the latest data, there are no specific recent major developments available for Corona Remedies Ltd. The company focuses on providing a diverse range of therapeutic solutions to improve healthcare outcomes.

## Revenue
In the third quarter of fiscal year 2026, Corona Remedies Ltd reported a total income of ₹344.66 crores. This represents a decrease of 5.2% from the previous quarter, Q2FY26, where the total income was ₹363.40 crores. There is no available data for the same quarter in the previous fiscal year, Q3FY25, to calculate year-over-year changes. The decline in revenue on a quarter-over-quarter basis indicates a reduction in the company's income over the recent quarter.

## Profitability
The company's financial performance in terms of profitability showed a contraction in Q3FY26. Profit Before Tax (PBT) was recorded at ₹55.19 crores, which is a decrease of 20.7% from the ₹69.61 crores reported in Q2FY26. The tax expense for Q3FY26 was ₹13.94 crores, down by 20.2% from the previous quarter. Consequently, Profit After Tax (PAT) was ₹41.27 crores, reflecting a 21.1% decline from the ₹52.32 crores achieved in Q2FY26. Earnings Per Share (EPS) also decreased by 21.1%, from ₹8.55 in Q2FY26 to ₹6.75 in Q3FY26. These metrics exhibit a downward trend in the company's profitability on a quarter-over-quarter basis.

## Operating Metrics
The financial data provided does not include specific operating metrics such as production volumes, sales growth, or operational efficiency ratios. However, the overall expenses decreased by 8.0% from ₹293.79 crores in Q2FY26 to ₹270.37 crores in Q3FY26. This reduction in expenses is notable in the context of the overall financial performance. The decline in both revenue and expenses indicates operational adjustments during the quarter. Key financial ratios such as the P/E ratio, debt-to-equity ratio, and current ratio are not calculable with the data provided, as it lacks information on share price, debt levels, and current assets/liabilities.